BMS 986036

Drug Profile

BMS 986036

Alternative Names: ARX-618; BMS-986036; FGF-21 mimetic proteins - Ambrx/Merck; PEG-FGF21; Pegylated-fibroblast growth factor-21 - Ambrx/Bristol-Myers Squibb

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambrx
  • Developer Bristol-Myers Squibb
  • Class Fibroblast growth factors; Obesity therapies; Polyethylene glycols; Proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists; Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrosis; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 29 Jun 2017 Bristol-Myers Squibb plans a phase I trial in Healthy volunteers in USA (NCT03198182)
  • 28 Jun 2017 Bristol-Myers Squibb initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03198182)
  • 23 Apr 2017 Updated efficacy data from a phase II trial in Non-alcoholic steatohepatitis presented at The International Liver Congress (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top